Intestinal Perforation Secondary to Bortezomib-Induced Autonomic Neuropathy.

It is essential to evaluate both the patient's prior conditions and the severity of the current clinical presentation when deciding on BTZ toxicity management. It seems prudent to consider the permanent discontinuation of the drug in patients who have experienced at least grade 3 intestinal neuropathy and have structural abnormalities or other risk factors for intestinal perforation. Trial Registration: NCT03710603.